Wall Street pummeled Sangamo Therapeutics Inc., at one point halving the value of the company's stock Thursday after it reported poor results in a pioneering clinical trial.
In a first-in-the-United-States clinical trial that attempted to edit genes inside people with a deforming and muscle-weakening lysosomal storage disease, the Richmond-based company (NASDAQ: SGMO) said its experimental drug saw limited success. That led anxious investors to drive Sangamo's stock from its opening price of $12.50…
